drugset / Trial / NCT04535193
Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation
Phase 1/2
Active not recruiting
10 enrolled
Innervate Radiopharmaceuticals LLC
Mount Sinai Hospital, New York · collab
Non-randomizedSequentialOpen-labelDiagnostic
Summary
This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.
Timeline
- Start
- 2021-11-05
- Primary completion
- 2025-03-07
- Completion
- 2026-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M-FLUOROBENZYLGUANIDINE | Diagnostic / imaging agent | — | Intravenous |